

A Study Evaluating the Safety and Pharmacokinetics of Aldurazyme® (Laronidase) in MPS I Patients Less Than 5 Years Old

Hôpital E. Herriot, Lyon, , France

Johannes Gutenberg Universität, Kinderklinik, Mainz, Germany

Sophia Children's Hospital, Rotterdam, , Netherlands

Willink Biochemical Genetics Unit Royal Hospital for Children, Manchester, , United Kingdom

The main objectives of this study are to evaluate the safety and pharmacokinetics (PK) of enzyme replacement therapy with recombinant human alpha-L-iduronidase [Aldurazyme® (laronidase)] in mucopolysaccharidosis I (MPS I) patients less than 5 years old. Efficacy measurements will also be evaluated in this study.